Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 243, Issue 11, 2005, Pages 1147-1152

  Takeuchi, Masaru ^a   Hokama, Hideyuki ^a   Tsukahara, Rintaroh ^a   Kezuka, Takeshi ^a   Goto, Hiroshi ^a   Sakai, Jun Ichi ^a   Usui, Masahiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Behcet's disease; Prognostic factor; Risk factor; Statistical analysis; Uveitis

Indexed keywords

HLA B51 ANTIGEN;

ADULT; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; EYE INFLAMMATION; FEMALE; FOLLOW UP; GENDER; HUMAN; HYPOPYON; IRIDOCYCLITIS; JAPAN; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL RECORD; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETINA BLOOD VESSEL; RETINA EXUDATE; RETINA VASCULITIS; REVIEW; RISK ASSESSMENT; UVEITIS; VISUAL ACUITY; VISUAL SYSTEM FUNCTION; VITREOUS OPACITY;

ADULT; AGE OF ONSET; BEHCET SYNDROME; DISEASE PROGRESSION; FEMALE; HLA-B ANTIGENS; HUMANS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VISION DISORDERS; VISUAL ACUITY;

EID: 31144456193     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-005-0005-8     Document Type: Review

References (33)

1. Barra C, Belfort Junior R, Abreu MT, Kim MK, Martins MC, Petrilli AM (1991) Behcet's disease in Brazil - a review of 49 cases with emphasis on ophthalmic manifestations. Jpn J Ophthalmol 35:339-346 1770675
2. Benezra D, Cohen E (1986) Treatment and visual prognosis in Behcet's disease. Br J Ophthalmol 70:589-592 3741823
3. Chajek T, Fainaru M (1975) Behcet's disease. Report of 41 cases and a review of the literature. Medicine (Baltimore) 54:179-196
4. Chung YM, Liu JH, Tsi ST (1986) Behcet's disease in Taiwan - a review of 53 cases. Jpn J Ophthalmol 30:318-323 3784143
5. De Smet MD, Bitar G, Mainigi S, Nussenblatt RB (2001) Human S-antigen determinant recognition in uveitis. Investig Ophthalmol Vis Sci 42:3233-3238
6. Demiroglu H, Barista I, Dundar S (1997) Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey. Ophthalmology 104:701-705 9111266
7. Er H, Evereklioglu C, Cumurcu T, Turkoz Y, Ozerol E, Sahin K, Doganay S (2002) Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behcet's disease. Br J Ophthalmol 86:653-657 10.1136/bjo.86.6.653
8. Ermakova NA, Alekberova ZS, Prokaeva TB (2003) Autoimmunity to S-antigen and retinal vasculitis in patients with Behcet's disease. Adv Exp Med Biol 528:279-281 12918707
9. Evereklioglu C, Er H, Turkoz Y, Cekmen M (2002) Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediat Inflamm 11:87-93 10.1080/09629350220131935
10. France R, Buchanan RN, Wilson MW, Sheldon MB Jr (1951) Relapsing iritis with recurrent ulcers of the mouth and genitalia (Behcet's syndrome); review: With report of additional case. Medicine (Baltimore) 30:335-355
11. Hamza M, Elleuch M, Slim A, Hamzaoui K, Ayed K (1990) Antibodies to Herpes simplex virus in patients with Behcet's disease. Clin Rheumatol 9:498-500 10.1007/BF02030511
12. Kazokoglu H, Saatci O, Cuhadaroglu H, Eldem B (1991) Long-term effects of cyclophosphamide and colchicine treatment in Behcet's disease. Ann Ophthalmol 23:148-151 2064258
13. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stubiger N (2003) Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423-431 10.1136/bjo.87.4.423
14. Lehner T, Stanford MR, Phipps PA, Sun JB, Xiao BG, Holmgren J, Shinnick T, Hasan A, Mizushima Y (2003) Immunopathogenesis and prevention of uveitis with the Behcet's disease-specific peptide linked to cholera toxin B. Adv Exp Med Biol 528:173-180 12918685
15. Martin DK, Nelms DC, Mackler BF, Peavy DL (1979) Lymphoproliferative responses induced by streptococcal antigens in recurrent aphthous stomatitis and Behcet's syndrome. Clin Immunol Immunopathol 13:146-155 10.1016/0090-1229(79)90058-8
16. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet I:1093-1096 10.1016/ S0140-6736(89)92381-7
17. Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K (1979) The eighth Frederick H. Verhoeff lecture presented by Saiichi Mishima, MD. Behcet's disease in Japan: Ophthalmologic aspects. Trans Am Ophthalmol Soc 77:225-279 397657
18. Mizushima Y, Matsumura N, Mori M, Shimizu T, Fukushima B, Mimura Y, Saito K, Sugiura S (1977) Colchicine in Behcet's disease. Lancet II:1037 10.1016/S0140-6736(77)92945-2
19. Mizushima Y (1988) Revised diagnostic criteria for Behcet's disease in 1987. Ryumachi 28:66-70 3388149
20. Mor F, Weinberger A, Cohen IR (2002) Identification of alpha-tropomyosin as a target self-antigen in Behcet's syndrome. Eur J Immunol 32:356-365 10.1002/1521-4141(200202)32:2<356::AID-IMMU356>3.0.CO;2-9
21. Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M (1982) Auto-oxidative damage in Behcet's disease-endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 49:247-255 7127901
22. Nussenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yancey K (1985) Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum 28:671-679 4004976
23. Pivetti Pezzi P, Gasparri V, De Liso P, Catarinelli G (1985) Prognosis in Behcet's disease. Ann Ophthalmol 17:20-25 3977213
24. Reimold AM (2002) TNF-alpha as therapeutic target: New drugs, more applications. Curr Drug Targets Inflamm Allergy 1:377-392 10.2174/ 1568010023344535
25. Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y (1995) Prognostic factors of vision in patients with Behcet disease. Ophthalmology 102:317-321 7862420
26. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet's disease. N Engl J Med 341:1284-1291 10.1056/NEJM199910213411707
27. Sancak B, Onder M, Oztas MO, Bukan N, Gurer MA (2003) Nitric oxide levels in Behcet's disease. J Eur Acad Dermatol Venereol 17:7-9 10.1046/ j.1468-3083.2003.t01-1-00574.x
28. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358:295-296 10.1016/ S0140-6736(01)05497-6
29. Tessler HH, Jennings T (1990) High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 74:353-357 2378842
30. Triolo G, Vadala M, Accardo-Palumbo A, Ferrante A, Ciccia F, Giardina E, Citarrella P, Lodato G, Licata G (2002) Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis 61:560-561 10.1136/ard.61.6.560
31. Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, Piette JC, LeHoang P (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm 8:293-301 10.1076/ocii.8.4.293.6453
32. Wong RC, Ellis CN, Diaz LA (1984) Behcet's disease. Int J Dermatol 23:25-32 6373632
33. Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, Ando K, Hijikata K, Izawa Y, Hayashi K, Numaga J, Fujino Y, Masuda K, Araie M (2004) Comparison of patients with Behcet's disease in the 1980s and 1990s. Ophthalmology 111:810-815 10.1016/j.ophtha.2003.07.018